The EDC3 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 liver adenocarcinoma cell line. This product provides a genetically disrupted EDC3 gene locus across a heterogeneous cell pool, enabling loss-of-function studies without clonal selection. The polyclonal format preserves population diversity while eliminating EDC3 function, serving as a robust model for investigating mRNA decapping and decay pathways.
The SK-HEP-1 host cell line originates from the ascites of a patient with liver adenocarcinoma and exhibits an adherent epithelial morphology. Widely employed as a hepatocellular carcinoma model, SK-HEP-1 cells are utilized in drug metabolism studies and possess endothelial-like characteristics, making them valuable for cancer biology and vascular mimicry research. Their genetic background supports the examination of liver cancer-specific post-transcriptional regulatory mechanisms.
EDC3 encodes a scaffold protein essential for the assembly of the mRNA decapping complex. It facilitates the removal of the 5′ cap structure, promoting 5′-to-3′ exonucleolytic decay mediated by XRN1. EDC3 interacts directly with DCP1A, DCP2, DDX6, the LSm1-7 complex, PATL1, and EDC4 to orchestrate processing body (P-body) formation. Its activity is regulated by stress stimuli, the mTOR pathway, MAP kinases, and RNA-binding proteins such as TTP/ZFP36. Downstream targets include AU-rich element-containing mRNAs, miRNA-targeted transcripts, and proto-oncogene mRNAs like c-MYC and FOS, as well as cytokine mRNAs such as TNF-alpha. Through these interactions, EDC3 modulates the levels of critical regulatory mRNAs.
In the SK-HEP-1 hepatocellular carcinoma context, EDC3 knockout provides a powerful tool to dissect the role of post-transcriptional gene regulation in cancer progression. Disruption of EDC3 may alter the stability of oncogenic mRNAs, impacting cell proliferation, apoptosis, and stress responses. This model enables the study of how dysregulated mRNA decay contributes to hepatocarcinogenesis and may reveal novel therapeutic targets within the mRNA surveillance pathway.
Researchers can employ this polyclonal knockout product in a variety of assays, including RNA-seq to profile transcriptomic changes, actinomycin D chase experiments to measure mRNA half-lives, RT-qPCR for candidate gene validation, luciferase reporter assays to assess mRNA stability, immunofluorescence to monitor P-body dynamics using markers such as DDX6 or DCP1A, and western blotting to confirm protein-level effects. Additionally, CLIP-seq can identify EDC3-associated transcripts. These applications facilitate detailed investigations into mRNA decay, P-body assembly, and post-transcriptional control in liver cancer. For further information, please contact Ascent Research.
